[The gastric tolerance of proglumetacin in man: comparison with indomethacin].
In healthy volunteers the effect of proglumetacin (Protaxon) on different functions of gastric and duodenal mucosa has been compared with that of indometacin in double-blind cross-over design. Pretreatment with 150 mg proglumetacin t.i.d. and 50 mg indometacin t.i.d. did not affect both human acid secretion as well as gastric microbleeding rate. Whereas treatment with 50 mg indometacin t.i.d. over 6 days induced gastric mucosal injury by about 2.4 +/- 0.25--as evaluated endoscopically--significantly lesser changes were seen following 150 mg proglumetacin t.i.d. (1.13 +/- 0.13) (p less than 0.001).
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D004311:Double-Blind Method; D005260:Female; D005750:Gastric Juice / Q000378:metabolism; D005753:Gastric Mucosa / Q000187:drug effects*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007210:Indoleacetic Acids / Q000009:adverse effects*; D007213:Indomethacin / Q000009:adverse effects*; D008297:Male; D010418:Pentagastrin; D011897:Random Allocation
D000893:Anti-Inflammatory Agents; D006454:Hemoglobins; D007210:Indoleacetic Acids; D010418:Pentagastrin; C019541:proglumetacin; D007213:Indomethacin
Untersuchungen zur Magenverträglichkeit von Proglumetacin am Menschen: Vergleich mit Indometacin.